Silence Therapeutics plc (SLN) Earnings History
Annual and quarterly earnings data from 1995 to 2025
Loading earnings history...
SLN EPS Growth (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
SLN Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2025 | 61.5% | -16056.0% | -15851.9% |
| 2024 | 72.7% | -146.4% | -104.7% |
| 2023 | 59.3% | -195.5% | -170.5% |
| 2022 | 37.8% | -281.9% | -232.4% |
| 2021 | 39.9% | -369.0% | -317.4% |
Download Data
Export SLN earnings history in CSV or JSON format
Free sign-in required to download data
Silence Therapeutics plc (SLN) Earnings Overview
As of May 8, 2026, Silence Therapeutics plc (SLN) reported trailing twelve-month net income of -$89M, reflecting +20.3% year-over-year growth. The company earned $-1.88 per diluted share over the past four quarters, with a net profit margin of -15851.9%.
Looking at the long-term picture, SLN's historical earnings data spans multiple years. The company achieved its highest annual net income of -$874,000 in fiscal 1995.
Silence Therapeutics plc is currently reporting a net loss, though operating performance should be evaluated in the context of growth investments and industry dynamics View revenue history →
Compared to peers including ALNY ($577M net income, 8.4% margin), ARWR (-$301M net income, -0.2% margin), SRPT ($65M net income, -32.5% margin), SLN has room to improve margins relative to the peer group. Compare SLN vs ALNY →
SLN Earnings vs Peers
Earnings metrics vs comparable public companies
SLN Historical Earnings Data (1995–2025)
31 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | -$89M | -95.6% | -$90M | $-1.89 | -15851.9% | -16056.0% |
| 2024 | -$45M | -4.7% | -$63M | $-2.37 | -104.7% | -146.4% |
| 2023 | -$43M | +14.0% | -$50M | $-3.48 | -170.5% | -195.5% |
| 2022 | -$50M | -27.7% | -$61M | $-3.78 | -232.4% | -281.9% |
| 2021 | -$39M | -21.1% | -$46M | $-1.35 | -317.4% | -369.0% |
| 2020 | -$33M | -66.2% | -$36M | $-1.11 | -594.0% | -654.3% |
| 2019 | -$20M | -6.4% | -$23M | $-0.78 | -8025.4% | -9317.2% |
| 2018 | -$18M | -1037.9% | -$21M | $-0.83 | - | - |
| 2017 | -$2M | +80.8% | -$14M | $-0.07 | -10112.5% | -89943.8% |
| 2016 | -$8M | -27.0% | -$12M | $-0.40 | -1096.1% | -1546.2% |
See SLN's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs SLN Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare SLN vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonSLN — Frequently Asked Questions
Quick answers to the most common questions about buying SLN stock.
Is SLN growing earnings?
SLN EPS is $-1.88, with earnings growth accelerating to +20.3%. This exceeds the 5-year CAGR of N/A. TTM net income reached $-89M.
What are SLN's profit margins?
Silence Therapeutics plc net margin is -15851.9%, with operating margin at -16056.0%. Below-average margins reflect competitive or cost pressures.
How consistent are SLN's earnings?
SLN earnings data spans 1995-2025. The accelerating earnings trend is +20.3% YoY. Historical data enables comparison across business cycles.